Dr. Ma and his team developed multiple High-Performance Liquid Chromatography (HPLC) methods in UK and Canada.
As a founder, Dr. Ma established Canadian Phytopharmaceuticals Corporation (CPC) in British Columbia, Canada. Prior to CPC's establishment, Dr. Ma proposed the ginsenoside content ratio in the ginseng plant. This allowed for future HPLC profile development for Panax species. The results have been recognized as international standards.
Dr. Ma actively promoted the concept of Standardization in botanical medicines.
Dr. Ma, as a player in pharmaceutical analysis, participated in the ginseng evaluation program closely working with American botanical council.
Dr. Ma collaborated with the Chinese State Drug Administration to organize the first International Conference on the Standardization of Phytopharmaceutical Products in Beijing, China.
Good Manufacturing Practice (GMP) required by Health Canada, all manufacturers in Canada must meet the requirements.
Dr. Ma signed the contract with the National Research Council of Canada for the research project on Goldenseal. He and his team focused researching on the analysis of formulated botanical products. He specifically focused on the analysis of multiple chemical constituents.
Dr. Ma and his team started working on the stability testing for Natural Health products which pushed the industry for Natural Health product to a higher level.
Dr. Ma and his team utilized RRLC methods to analyze most popular botanical extracts and finished products such as Rhodiola, Epimedium and different ginseng species.
A series of scientific research papers were published by Dr. Ma and his research team on the formulated botanical products.
Dr. Ma and his team's research work on the analysis of Rhodiola, Reish mushroom, Panax notoginseng, Ginkgo biloba, have been accepted by the United States Pharmacopoeia as monographs and international standards.